All Categories

Successful treatment of pulmonary arterial hypertension in a 2-month-old female infant with incontinentia pigmenti: A case report

Marta Marcia, Paola Coppo, Giuseppe Alberto Annoni, Gaetana Ferraro, Gabriella Agnoletti, Giuseppe Antonio MazzaCity of Health and Science Hospital.Italy Annals of Pediatric CardiologyAnn Pediatr Cardiol 2023; 16: 297-300DOI: 10.4103/apc.apc_75_23 AbstractIncontinentia pigmenti (IP) is a rare X-linked dominant neuroectodermal dysplasia affecting almost exclusively females. It is caused by loss-of-function mutations in the inhibitor of kappa light polypeptide […]

Successful treatment of pulmonary arterial hypertension in a 2-month-old female infant with incontinentia pigmenti: A case report Read More »

Successful hybrid management of hypertensive patent ductus arteriosus with unilateral absence of the right pulmonary artery – A case report

Jayitri Mazumder, Debasree Gangopadhyay, Mahua Roy, Anoop Singh, Somrita Laha, Joyeeta DuttaRabindranath Tagore International Institute of Cardiac Sciences.India Annals of Pediatric CardiologyAnn Pediatr Cardiol 2023; 16: 293-296DOI: 10.4103/apc.apc_54_23 AbstractUnilateral absence of pulmonary artery (UAPA) can be either isolated or associated with other congenital cardiac defects. It is a rare congenital lesion with a diverse clinical presentation.

Successful hybrid management of hypertensive patent ductus arteriosus with unilateral absence of the right pulmonary artery – A case report Read More »

Case Records of the Massachusetts General Hospital. Case 23511

Tracy B. MalloryMassachusetts General Hospital.United States New England Journal of MedicineNew Eng J Med 1937; 217: 1045-1049DOI: Not Available AbstractAbstract Not Available CategoryClass II. Pulmonary Hypertension Associated with Pulmonary Vein StenosisSymptoms and Findings Associated with Pulmonary Vascular DiseasePulmonary Vascular Pathology Age Focus: Pediatric Pulmonary Vascular Disease Fresh or Filed Publication: Filed (PHiled). Greater than 1-2

Case Records of the Massachusetts General Hospital. Case 23511 Read More »

Emerging Epigenetic Targets and Their Molecular Impact on Vascular Remodeling in Pulmonary Hypertension

A. Dushani, C. U. Ranasinghe, T. M. Parinda B. Tennakoon, Margaret A. SchwarzBoston Children’s Hospital and Harvard Medical School. Indiana University School of Medicine.United States CellsCells 2024; 13:DOI: 10.3390/cells13030244 AbstractPulmonary Hypertension (PH) is a terminal disease characterized by severe pulmonary vascular remodeling. Unfortunately, targeted therapy to prevent disease progression is limited. Here, the vascular cell populations

Emerging Epigenetic Targets and Their Molecular Impact on Vascular Remodeling in Pulmonary Hypertension Read More »

Transient abnormal myelopoiesis requiring advanced neonatal intensive care treatment

Maria Chalia, Emilie Seager, Anupama Rao, Simon HannamGreat Ormond Street Hospital for Children.United Kingdom Acta PaediatricaActa Paediatr 2024; DOI: 10.1111/apa.17142 AbstractAim: Five to thirty percent of neonates with trisomy 21 develop transient abnormal myelopoiesis (TAM) with a high mortality rate. The aim of the study was to identify contributing factors that determine mortality and need for chemotherapy

Transient abnormal myelopoiesis requiring advanced neonatal intensive care treatment Read More »

[Clinical and genetic analysis of a patient with HUPRA syndrome due to missense variants of SARS2 gene and literature review]

J. Huang, Q. Y. Li. W. Ji, X.F. Guo, X. H. HuFujian Children’s Hospital. Beijing Anzhen Hospital and Capital Medical University. Shanghai Jiaotong University School of Medicine and Shanghai Children’s Medical Center. Fujian Provincial Maternity and Children’s Hospital. Xinhua Hospital.China Zhonghua Xin Xue Guan Bing Za Zhi 2024; 52: 172-179DOI: 10.3760/cma.j.cn112148-20231009-00268 Abstract (English)Objective: To explore the clinical

[Clinical and genetic analysis of a patient with HUPRA syndrome due to missense variants of SARS2 gene and literature review] Read More »

Inhaled Nitric Oxide in Neonatal Pulmonary Hypertension

Michael W. Cookson, John P. KinsellaUniversity of Colorado Anschutz School of Medicine and Children’s Hospital Colorado.United States Clinics in PerinatologyClin Perinatol 2024; 51: 95-111DOI: 10.1016/j.clp.2023.11.001 AbstractPivotal trials investigating the use of inhaled nitric oxide (iNO) in the 1990s led to approval by the Food and Drug Administration in 1999. Inhaled nitric oxide is the only approved

Inhaled Nitric Oxide in Neonatal Pulmonary Hypertension Read More »

Oxygen Targets in Neonatal Pulmonary Hypertension: Individualized, “Precision-Medicine” Approach

Satyan Lakshminrusimha, Steven H. AbmanUniversity of California, Davis Children’s Hospital. University of Colorado Anschutz Medical Campus.United States Clinics in PerinatologyClin Perinatol 2024; 51: 77-94DOI: 10.1016/j.clp.2023.12.003 AbstractOxygen is a specific pulmonary vasodilator. Hypoxemia causes pulmonary vasoconstriction, and normoxia leads to pulmonary vasodilation. However, hyperoxia does not enhance pulmonary vasodilation but causes oxidative stress. There are no clinical

Oxygen Targets in Neonatal Pulmonary Hypertension: Individualized, “Precision-Medicine” Approach Read More »

Comorbidities and Late Outcomes in Neonatal Pulmonary Hypertension

Emily S. Stieren, Deepika Sankaran, Satyan Lakshminrusimha, Catherine A. RottkampUniversity of California, Davis.United States Clinics in PerinatologyClin Perinatol 2024; 51: 271-289DOI: 10.1016/j.clp.2023.10.002 AbstractLong-term outcomes of persistent pulmonary hypertension of newborn (PPHN) depend on disease severity, duration of ventilation, and associated anomalies. Congenital diaphragmatic hernia survivors may have respiratory morbidities and developmental delay. The presence of PPHN

Comorbidities and Late Outcomes in Neonatal Pulmonary Hypertension Read More »

Randomized Controlled Trials of Pulmonary Vasodilator Therapy Adjunctive to Inhaled Nitric Oxide for Persistent Pulmonary Hypertension of the Newborn: A Systematic Review

Kristen Coletti, K. Taylor Wild, Elizabeth E. Foglia, Suzan Cochius-den Otter, Haresh KirpalaniChildren’s Hospital of Philadelphia and University of Pennsylvania. Erasmus MC University Medical Center.United States and Netherlands Clinics in PerinatologyClin Perinatol 2024; 51: 253-269DOI: 10.1016/j.clp.2023.11.009 AbstractInhaled nitric oxide (iNO) is a pulmonary vasodilator considered standard of care to treat persistent pulmonary hypertension of the newborn.

Randomized Controlled Trials of Pulmonary Vasodilator Therapy Adjunctive to Inhaled Nitric Oxide for Persistent Pulmonary Hypertension of the Newborn: A Systematic Review Read More »

Scroll to Top